METiS Therapeutics Analysis: $252M Raised
What is METiS Therapeutics?
AI-driven drug discovery and delivery solutions
Location
Cambridge, United States
Employees
1-10
Founded
2017
Product Features & Capabilities
- AI and ML-driven drug discovery platform
- High-throughput in vivo screening for LNPs
- Proprietary predictive AI platform for drug development
- Targeted delivery systems for RNA and gene therapies
Use Cases
Discover unique lipid nanoparticles with high delivery efficiency; Develop therapeutics targeting multiple organ systems; Collaborate on external programs for AI and ML-developed nanoparticles; Enhance drug delivery systems for serious diseases; Utilize AI for novel therapeutic development
How much METiS Therapeutics raised
Funding - $252M
Other Considerations
Raised $86 million in Series A financing; Appointed Mark Herbert as Chief Business Officer; Partnered with Evopoint Biosciences for licensing; Joined Roche Accelerator for drug development support
Find more companies like METiS Therapeutics
See something that needs updating? Suggest edits to this profile.
